Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.
With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.
Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.
Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.
Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.
Rhea-AI Summary
Takeda announces positive topline results from a Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. The trial demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8. TAK-861 was found to be generally safe and well-tolerated, with no treatment-related serious adverse events reported. Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024. The results have no impact on the full-year consolidated reported forecast for the fiscal year ending March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
-
Rhea-AI Summary
Takeda announces the departure of CFO Costa Saroukos, effective April 1, 2024, with Milano Furuta set to succeed him. Saroukos has played a key role in Takeda's transformation and the successful acquisition of Shire PLC. Furuta, with a strong financial background and global experience, is well-equipped to lead Takeda's finance organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
-
Rhea-AI Summary
Takeda announced two new U.S. FDA approvals in FY2023 Q3 for FRUZAQLA and ADZYNMA, enhancing its portfolio. The company reported a revenue growth of +4.6% at AER, flat at CER, and a core operating profit change of -12.7% at CER. Takeda's financial results show a strong momentum in its Growth & Launch Products, offsetting the revenue impact of generic entrants. The company remains on track towards its full-year Management Guidance, reflecting significant generic impact, lower coronavirus vaccines revenue, and investment in R&D and data, digital, and technology to secure long-term competitiveness. Takeda's Chief Financial Officer, Costa Saroukos, emphasized the company's vision to discover and deliver life-transforming treatments and the improvement in their debt profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
Rhea-AI Summary
Takeda has received FDA approval for GAMMAGARD LIQUID as an intravenous immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This milestone follows the recent FDA approval of HYQVIA for maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults with CIDP. The approval is based on results from a prospective, open-label, single-arm, multicenter clinical study that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety, and tolerability of HYQVIA in adults with CIDP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary
Takeda's HYQVIA has been approved by the European Commission for the treatment of chronic inflammatory demyelinating polyneuropathy, offering patients a once-monthly maintenance therapy option. The approval expands Takeda's portfolio of immunoglobulin therapies for patients with neuroimmunological disorders. The approval is based on a Phase 3 trial that showed a significant reduction in CIDP relapse rate with HYQVIA versus placebo, with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary
Cognizant (NASDAQ: CTSH) has expanded its agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support Takeda's digital transformation strategy. The partnership aims to attract additional technology talent and expand Takeda's Innovation Capability Center operations. Cognizant will help Takeda deliver digital capabilities as a service and modernize its operational model, aiming to accelerate Takeda's digital transformation journey and speed time to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) has been recognized as a global Top Employer for the seventh consecutive year, achieving certification in 24 countries. The company was evaluated based on HR Best Practices Survey, covering 20 topics including people strategy, work environment, talent acquisition, learning, diversity & inclusion, and well-being. Takeda's commitment to prioritizing talent, well-being, learning, and diversity, equity, and inclusion has been acknowledged by the Top Employers Institute. The company excelled in areas of ethics & integrity, purpose & values, business strategy, employer branding, and organization & change.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
Takeda's HYQVIA, a combination of immunoglobulin and hyaluronidase, has been approved by the FDA for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse in adults. The approval is based on a Phase 3 study showing a statistically significant difference in relapse rate between HYQVIA and placebo. HYQVIA is the only subcutaneous immunoglobulin infusion that can be administered by a healthcare professional or self-administered after appropriate training, offering a personalized maintenance treatment option for adults with CIDP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
-
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) announced that LIVTENCITY (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment. LIVTENCITY is the first and only inhibitor of CMV-specific UL97 protein kinase in China for this indication. The approval is based on the Phase 3 SOLSTICE trial, where LIVTENCITY was superior to conventional therapies at Week 8 for the primary endpoint of confirmed CMV viremia clearance in post-transplant adults with refractory CMV infection. This approval marks the 12th approval of LIVTENCITY around the world for post-transplant CMV refractory to prior therapies, including major markets like the United States, Canada, Australia, and the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
Rhea-AI Summary
Takeda (TSE:4502/NYSE:TAK) receives positive CHMP opinion for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for CIDP patients, offering a potential once-monthly subcutaneous treatment option. The Phase 3 ADVANCE-CIDP 1 study met its primary endpoint, demonstrating a statistically significant reduction in relapse rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
FAQ
What is the current stock price of Takeda Pharm (TAK)?
The current stock price of Takeda Pharm (TAK) is $14.06 as of February 21, 2025.
What is the market cap of Takeda Pharm (TAK)?
The market cap of Takeda Pharm (TAK) is approximately 43.9B.
What are Takeda Pharmaceutical's core therapeutic areas?
Takeda focuses on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
Where is Takeda Pharmaceutical headquartered?
Takeda is headquartered in Tokyo, Japan.
What recent collaborations has Takeda Pharmaceutical entered into?
Takeda recently entered a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation to incubate early drug discovery programs.
How diversified is Takeda's revenue geographically?
Takeda's revenue is geographically diversified: 50% from the US, 20% from Japan, and 20% from Europe and Canada.
What was Takeda's revenue in fiscal 2023?
Takeda's revenue in fiscal 2023 was JPY 4.3 trillion.
Who can benefit from Takeda's new drug NBI-1065845?
NBI-1065845 is targeted at patients with major depressive disorder who have not benefited from at least one existing antidepressant treatment.
What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?
The joint venture focuses on incubating early drug discovery programs to advance academic discoveries into practical medical treatments.
How long has Takeda been in the pharmaceutical industry?
Takeda has been a leader in the pharmaceutical industry for over two centuries.
In how many countries does Takeda operate?
Takeda operates in approximately 80 countries.
How does Takeda contribute to the field of major depressive disorder treatment?
Takeda collaborates with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment showing positive Phase 2 results for MDD.
Takeda Pharm